COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01744626
Recruitment Status : Completed
First Posted : December 7, 2012
Last Update Posted : April 19, 2016
Information provided by (Responsible Party):
Celgene Corporation

Brief Summary:
This is a dose finding study using a 3 + 3 dose escalation and expansion design to determine a Not Tolerated Dose (NTD), Optimal Biological Effect Dose (OBE) and / or Maximum Tolerated Dose (MTD). These data will be used to establish a Recommended Phase 2 Dose (RP2D) for the combination of CC-292 and Rituximab in subjects with CLL.

Condition or disease Intervention/treatment Phase
Leukemia Lymphocytic Chronic B-Cell Drug: CC-292 Drug: Rituximab Phase 1

Detailed Description:

This dose finding study uses a 3 + 3 dose escalation and expansion design to establish the recommended Phase 2 dose (RP2D). Treatment will consist 28 day treatment cycles with a single Rituximab infusion per cycle for 6 cycles and twice daily (days 1-28) administration of CC-292 with a starting dose cohort of 375mg twice a day. Following safety review of the data from the initial cohort and confirmation that the initial dose is tolerable, the next dose level will be enrolled with a once per cycle Rituximab infusion for 6 cycles and twice daily CC-292 at 500 mg.

Determination of the maximum tolerated dose and/or optimal biologic effect will be used to establish a dose for evaluation in an expansion cohort of 24 subjects. Evaluation of the data for subjects in the expansion cohorts will result in establishment of a RP2D.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b, Multi-center, Open Label, Study to Determine the Safety and Activity of CC-292 in Combination With Rituximab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.
Study Start Date : December 2012
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Arm Intervention/treatment
Experimental: CC-292 with Rituximab
Dose Escalation
Drug: CC-292
Cohort 1: 375 mg CC-292 will be administered twice a day on Days 1-28 Cohort 2: 500 mg CC-292 will be administered twice a day on Days 1-28

Drug: Rituximab
Cohort 1: Rituximab once per cycle Cohort 2: Rituximab once per cycle

Primary Outcome Measures :
  1. Adverse Events [ Time Frame: Up to a year ]
    Number of participants with adverse events

Secondary Outcome Measures :
  1. PK-Cmax [ Time Frame: Up to 15 days ]
    Maximum observed plasma concentration

  2. PK-Tmax [ Time Frame: Up to 15 days ]
    Time to maximum observed plasma concentration of CC-292 in combination with Rituximab.

  3. PK-λz [ Time Frame: Up to 15 days ]
    Terminal phase rate constant.

  4. PK-t1/2 [ Time Frame: Up to 15 days ]
    Estimate of the terminal phase half-life in plasma.

  5. PK-AUC (0-t) [ Time Frame: Up to 15 days ]
    Area under the plasma concentration-time curve from time zero to the last quantifiable time point.

  6. PK-AUC0-∞ [ Time Frame: Up to 15 days ]
    Area under the plasma concentration time curve from time zero extrapolated to infinity.

  7. Efficacy [ Time Frame: Up to 2 years ]
    To evaluate the preliminary efficacy of CC-292 in combination with Rituximab, including Response Rate, Duration of Response and Progression-Free Survival

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male and female subjects 18 years of age and older at the time of signing the informed consent document.
  2. Understand and voluntarily sign an informed consent document (ICD) prior to any study related assessments/procedures being conducted.
  3. Able to adhere to the study visit schedule and other protocol requirements.
  4. Body weight ≥ 50 kg.
  5. Must have a documented diagnosis of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (International Workshop) guidelines for the diagnosis and treatment of CLL (Appendix A), or lymphoma guidelines (Appendix B) for diagnosis and treatment of SLL by investigator assessment.
  6. Have failed ≥ 1 previous treatments for CLL/SLL, and have relapsed or refractory disease following last prior treatment.

    1. Refractory is defined as CLL/SLL that does not achieve at least a partial response (PR) to therapy or that progresses within 6 months of treatment. Relapsed CLL/SLL refers to disease that progresses after ≥ 6 months in subjects who had achieved a PR or complete response (CR) to therapy.
    2. Subjects must have failed, refused, be ineligible, or not otherwise appropriate, per the investigator's judgment, for autologous stem cell transplant (SCT) unless enrollment in this study is anticipated to debulk lesions in preparation for SCT.
  7. Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤ 2
  8. Life expectancy of at least 3 months form the time of signing the ICD.
  9. Females of childbearing potential (FCBP)must have a negative medically supervised pregnancy test prior to starting of study therapy.
  10. Male subjects must:

    1. Agree to use a condom during sexual contact with a FCBP, even if they have had a vasectomy, throughout study drug treatment, during any dose interruption and for 28 days after end of study therapy.
    2. Agree to not donate semen during study drug treatment and for 28 days after end of study drug treatment.
  11. Ability to swallow oral capsules without difficulty.
  12. Have an echocardiogram or multigated acquisition scan of the heart demonstrating left ventricular ejection fraction (LVEF) ≥ 50% or the institution's lower limit of normal.
  13. Have recovered from adverse, toxic effects of prior therapies to Grade ≤ 1 National Cancer Institute Common Terminology Criteria for Adverse Events (NCI/CTCAE) version 4.03 except for alopecia and peripheral neuropathy. This requirement will be subordinate to specific clinical and laboratory criteria that are otherwise specifically addressed in these inclusion/exclusion criteria.

Exclusion Criteria:

  1. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
  2. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
  3. Any condition that confounds the ability to interpret data from the study.
  4. Autologous stem cell transplant within 3 months of screening date.
  5. Uncontrolled intercurrent illness including, but not limited to:

    1. Ongoing or active infection requiring parenteral antibiotics.
    2. Uncontrolled diabetes mellitus as defined by the investigator.
    3. Chronic symptomatic congestive heart failure (Class III or IV of the New York Heart. Association Classification for Heart Disease; AppendixG).
    4. Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months of signing the ICD.
    5. Clinically significant cardiac arrhythmia that is symptomatic or requires treatment, or asymptomatic sustained ventricular tachycardia. Subjects with controlled atrial fibrillation that is asymptomatic are eligible.
  6. Pregnant or lactating females.
  7. Prior history of malignancies, unless the subject has been free of the disease for ≥ 3 years of signing the informed consent. Exceptions to the ≥ 3 year time limit include history of the following:

    1. Basal cell carcinoma of the skin.
    2. Squamous cell carcinoma of the skin.
    3. Carcinoma in situ of the cervix.
    4. Carcinoma in situ of the breast.
    5. Carcinoma in situ of the bladder.
    6. Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b). (The TNM staging system is based on the extent of the tumor (T), whether cancer cells have spread to nearby (regional) lymph nodes (N), and whether distant (to other parts of the body) metastasis (M) has occurred).
  8. Known seropositivity for or history of active viral infection with Human Immunodeficiency Virus (HIV).
  9. Seropositive for or active viral infection with Hepatitis B virus (HBV):

    1. HBV surface antigen positive.
    2. HBV surface antigen negative, HBV surface antibody positive and/or HBV core antibody positive and detectable viral deoxyribonucleic acid (DNA).

      Note: Subjects who are HBV surface antigen negative and viral DNA negative are eligible.

    3. Subjects who had HBV but have received an antiviral treatment and show no detectable viral DNA within 6 months of signing the ICD are eligible.
    4. Subjects who exhibit the classical vaccination profile of HBV surface antibody positive, HBV core antibody negative, and HBV surface antigen negative are eligible.
  10. Known seropositivity for or active viral infection with Hepatitis C virus (HCV).
  11. Subjects who are at a high risk for a thromboembolic event and are not willing to take venous thromboembolic event (VTE) prophylaxis.
  12. Any of the following laboratory abnormalities:

    1. Absolute neutrophil count (ANC) ≤ 1,000 cells/mm3 (1.0 x 109/L) unless secondary to bone marrow involvement by lymphoma as demonstrated by recent bone marrow aspiration and bone marrow biopsy.
    2. Platelet count ≤ 50,000/mm3 (50 x 109/L) unless secondary to bone marrow involvement by lymphoma as demonstrated by recent bone marrow aspiration and bone marrow biopsy. Note that growth factors or transfusions should not be administered during screening for the sole purpose of helping a subject exceed these exclusionary laboratory values.
    3. Serum Aspartate Transaminase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) or Alanine Transaminase/Serum Glutamic Pyruvate Transaminase (ALT/SGPT) > 3.0 x Upper Limit of Normal (ULN) or > 5.0 x ULN in cases of documented liver involvement by lymphoma.
    4. Serum bilirubin > 1.5 x ULN or > 3.0 x ULN in cases of Gilbert's Syndrome and documented liver involvement by lymphoma.
    5. Calculated creatinine clearance using the Cockcroft-Gault formula (Cockcroft, 1976).

      • For subjects enrolling in Part 1 creatinine clearance value must be < 30 mL/min
      • For subjects enrolling in Part 2 creatinine clearance value must be < 60 mL/min
    6. Corrected QT interval (QTc) prolongation (defined as a QTc > 450 msec for males and > 470 msec for females [Fridericia's correction] echocardiograms (ECGs) or other clinically significant ECG abnormalities as assessed by the investigator. An average of 3 QTc intervals may be obtained if necessary.
    7. Evidence of Tumor Lysis Syndrome (TLS) per the Cairo-Bishop definition of laboratory TLS ([Appendix F] subjects may be enrolled upon correction of electrolyte abnormalities).
  13. Prior exposure to Bruton Tyrosine Kinase inhibitors.
  14. Chemotherapy, radiotherapy, investigational anti cancer therapy or major surgery within 28 days of Day 1 dosing.
  15. Use of systemic corticosteroids in doses greater than prednisone equivalent 20 mg/day within 3 weeks prior to the first dose of study drug treatment.
  16. Concomitant use of medicines known to cause QT prolongation or torsades de pointes (Appendix I).
  17. Chronic use of H2 antagonists or proton pump inhibitors or their use within 7 days of first dose of study drug treatment. Subjects with chronic gastroesophageal reflux disease, dyspepsia, and peptic ulcer disease, should be carefully evaluated for their suitability for this treatment prior to enrollment in this study.
  18. Gastrointestinal abnormalities including the ability to take oral medication, require intravenous (IV) alimentation, or prior surgical procedures affecting absorption.
  19. History of hypersensitivity reaction to Rituximab.
  20. Any vaccinations incorporating the use of a live vaccine within 3 weeks from first dose.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01744626

Layout table for location information
United States, Alabama
Clearview Cancer Institute
Huntsville, Alabama, United States, 35805
United States, Indiana
Horizon Oncology Research, Inc
Lafayette, Indiana, United States, 47905
United States, New Jersey
Hackensack UMC
Hackensack, New Jersey, United States, 07601
United States, Tennessee
The West Clinic
Memphis, Tennessee, United States, 38120
Universitätsklinik Ulm
Ulm, Bayern, Germany, 89070
Städt. Klinikum München-Schwabing
Bayern, Germany, 80804
Universitatsklinikum Wurzburg
Bayern, Germany, 907080
Universitätsklinik Köln
Köln, Germany, 50924
Sponsors and Collaborators
Celgene Corporation
Layout table for investigator information
Study Director: Kenichi Takeshita, MD Celgene
Layout table for additonal information
Responsible Party: Celgene Corporation Identifier: NCT01744626    
Other Study ID Numbers: CC-292-CLL-002
2012-003767-21 ( EudraCT Number )
First Posted: December 7, 2012    Key Record Dates
Last Update Posted: April 19, 2016
Last Verified: April 2016
Keywords provided by Celgene Corporation:
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents